The computing giant and gene-chip maker have announced a partnership to supply clinical genomics capabilities to medical research facilities and drug makers.
Computing industry giant IBM and gene-chip maker Affymetrix have announced a partnership to supply clinical genomics capabilities to medical research facilities and drug makers.
Affymetrix expects to provide its genotyping platform, while IBM will offer systems integration and regulatory compliance services. This will allow companies to quickly assemble a lab built for genetic and genomic profiling as well as within regulatory requirements. Systems will cost in the range of $1 million to $2 million; a high-end system could process 100,000 arrays a year.
Next, the two companies expect to set their sights on using clinical genomics to improve trial design.
Read the full story at Bio-IT World